Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
Illumina, Inc. entered into an underwriting agreement to issue and sell $300,000,000 aggregate principal amount of its 4.950% notes due 2029. The transaction is with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., acting as representatives of the underwriters, and is expected to close on August 17, 2026, subject to customary closing conditions.
Illumina expects to use the net proceeds from these notes, together with cash on hand, to repay its 4.650% notes due September 9, 2026. The new notes will be issued under an effective shelf Registration Statement on Form S-3 (No. 333-281921). The detailed underwriting agreement is included as an exhibit and incorporated by reference.
ILLUMINA, INC. filed an initial insider ownership report for Julie Ann Coletti, who serves as Chief Legal Officer. The filing lists her as an officer but does not disclose any reportable transactions or equity holdings, serving solely to establish her status as a reporting person.
Illumina, Inc. plans a new offering of senior unsecured Notes under its automatic shelf registration, with specific maturity and coupon to be set at pricing. The Notes will be unsubordinated obligations, ranking equally with Illumina’s existing unsecured notes and effectively junior to any secured debt and to all liabilities of subsidiaries.
The company discloses existing indebtedness of $2.0 billion as of June 28, 2026 and subsidiary liabilities of $831 million. The Notes are callable at Illumina’s option, and upon a Change of Control Triggering Event holders may require repurchase at 101% of principal plus accrued interest. Illumina expects to use net proceeds for general corporate purposes, including repaying its 4.650% notes due September 9, 2026, of which $500.0 million was outstanding as of June 28, 2026. The Notes will be issued in minimum denominations of $2,000, in book-entry form through DTC, with no sinking fund and no planned exchange listing.
Sullivan Michael C reported acquisition or exercise transactions in this Form 4 filing.
Illumina, Inc. granted Chief Commercial Officer Michael C. Sullivan equity awards on August 5, 2026. These included 4,503 restricted stock units of common stock at $199.87 per share, vesting 25% on each of the first four anniversaries of grant. He also received two performance stock unit awards of 5,254 units each, settling in common shares on December 31, 2028 based on three-year non-GAAP EPS growth and relative total shareholder return, with actual payout ranging from 0% to 250% of target, subject to continued service.
Illumina, Inc. describes a proposed resolution of Delaware litigation brought by Icahn Partners LP and related plaintiffs challenging the company’s approximately $8 billion acquisition of GRAIL, Inc. Illumina and current and former directors entered a Release Agreement on August 21, 2025, providing mutual releases with no payments by any party.
Under the agreement, the action Icahn Partners LP v. deSouza will be dismissed with prejudice as to those plaintiffs only and without prejudice to all other Illumina stockholders, including plaintiffs in three separate derivative actions that remain pending. The Delaware Court of Chancery will hold a hearing on the proposed dismissal on November 2, 2026, at 1:30 p.m. Eastern time. Stockholders of record on April 3, 2023 and current stockholders as of July 31, 2026 receive notice and may object under specified procedures. Defendants continue to deny the plaintiffs’ claims, and the court has made no findings on the merits.
Illumina, Inc. director Keith A. Meister reported that private investment funds for which Corvex Management LP acts as investment adviser sold 741,127 shares of Illumina common stock on August 4–5, 2026, in multiple transactions described as open‑market or private sales at weighted‑average prices between $196.74 and $203.28 per share. The securities are held for Corvex‑advised funds’ accounts, and both Corvex and Meister disclaim beneficial ownership beyond their pecuniary interests. A footnote corrects earlier Section 16 reports, stating the funds indirectly owned 2,830,552 shares before these sales, while Meister continues to hold 6,780 shares directly.
Illumina, Inc. (ILMN) has a planned sale of Common Stock under Rule 144. The notice covers up to 840,000 shares of common stock, par value $0.01 per share, to be sold through Goldman Sachs & Co. LLC on the Nasdaq Global Select Market, with an aggregate market value of $166,454,400 as of August 4, 2026.
The filing also lists prior sales by Corvex Management LP over the past three months, including 225,067 shares for $32,760,165.38 on May 13, 2026 and several additional sales in May and June 2026.
Illumina, Inc. reports that Chief Legal Officer Scott M. Davies sold 615 shares of common stock on 2026-07-30 at $200.00 per share in a sale categorized as an open market or private transaction. The transaction was effected under a Rule 10b5-1 trading plan, and he now directly holds 20,338 shares of Illumina common stock.
Illumina, Inc. (ILMN) has a notice of proposed sale under Rule 144 for 615 shares of common stock, with an indicated aggregate market value of $119,814.30, to be sold through Morgan Stanley Smith Barney LLC on or after July 30, 2026 on NASDAQ.
The filing also lists prior sales under a Rule 10b5-1 trading plan for Scott Davies: 615 shares of common stock for $110,700.00 on June 25, 2026 and 615 shares for $98,400.00 on May 29, 2026, all related to restricted stock units issued by Illumina.